Jensen HJ - Search Results

1

Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.

Sundberg AL, Almqvist Y, Orlova A, Blomquist E, Jensen HJ, Gedda L, Tolmachev V, Carlsson J. Sundberg AL, et al. Among authors: jensen hj. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1348-56. doi: 10.1007/s00259-003-1308-9. Epub 2003 Aug 21. Eur J Nucl Med Mol Imaging. 2003. PMID: 12937952

2

In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.

Nestor M, Persson M, van Dongen GA, Jensen HJ, Lundqvist H, Anniko M, Tolmachev V. Nestor M, et al. Among authors: jensen hj. Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1296-304. doi: 10.1007/s00259-005-1848-2. Epub 2005 Jul 19. Eur J Nucl Med Mol Imaging. 2005. PMID: 16028065

3

In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.

Almqvist Y, Orlova A, Sjöström A, Jensen HJ, Lundqvist H, Sundin A, Tolmachev V. Almqvist Y, et al. Among authors: jensen hj. Cancer Biother Radiopharm. 2005 Oct;20(5):514-23. doi: 10.1089/cbr.2005.20.514. Cancer Biother Radiopharm. 2005. PMID: 16248767

4

211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.

Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L. Bäck T, et al. J Nucl Med. 2005 Dec;46(12):2061-7. J Nucl Med. 2005. PMID: 16330571 Free article.

5

Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.

Persson MI, Gedda L, Jensen HJ, Lundqvist H, Malmström PU, Tolmachev V. Persson MI, et al. Among authors: jensen hj. Oncol Rep. 2006 Mar;15(3):673-80. doi: 10.3892/or.15.3.673. Oncol Rep. 2006. PMID: 16465429

6

Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.

Cheng J, Ekberg T, Engström M, Nestor M, Jensen HJ, Tolmachev V, Anniko M. Cheng J, et al. Among authors: jensen hj. Laryngoscope. 2007 Jun;117(6):1013-8. doi: 10.1097/MLG.0b013e31804b1a6d. Laryngoscope. 2007. PMID: 17440426

7

Biodistribution of 211At-labeled humanized monoclonal antibody A33.

Almqvist Y, Steffen AC, Lundqvist H, Jensen H, Tolmachev V, Sundin A. Almqvist Y, et al. Cancer Biother Radiopharm. 2007 Aug;22(4):480-7. doi: 10.1089/cbr.2007.349A. Cancer Biother Radiopharm. 2007. PMID: 17803442

8

Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with ²¹¹At-MX35-F(ab')₂: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival.

Bäck T, Chouin N, Lindegren S, Kahu H, Jensen H, Albertsson P, Palm S. Bäck T, et al. J Nucl Med. 2017 Apr;58(4):598-604. doi: 10.2967/jnumed.116.178327. Epub 2016 Sep 29. J Nucl Med. 2017. PMID: 27688477 Free article.

9

Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.

Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, Warnhammar E, Jacobsson L. Elgqvist J, et al. J Nucl Med. 2005 Mar;46(3):464-71. J Nucl Med. 2005. PMID: 15750160 Free article.

10

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L. Elgqvist J, et al. J Nucl Med. 2005 Nov;46(11):1907-15. J Nucl Med. 2005. PMID: 16269606 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters